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Abstract
Background:  Asthma  and  Allergic  Rhinitis  (AR)  are  two  chronic  inflammatory  diseases  that  are
often concomitant.  The  Control  of  Allergic  Rhinitis  and Asthma  Test  (CARAT)  was  developed
to evaluate  the  control  of  these  diseases  from  the  patients’  perspective.  Its  performance  in
asthma patients  without  AR  has  not  been  previously  studied.
Aim: To  test  the  hypothesis  that  CARAT  can  be used  to  assess  asthma  control  in  patients  with
asthma and  without  AR.
Methods:  A  cross-sectional  study  was  conducted  in  3  primary  healthcare  centres  in Northern
Portugal.  Adult  patients  identified  in the Electronic  Patient  Record  with  a  diagnosis  of  asthma
were invited  to  participate.  CARAT  was  used  to  assess  asthma  control  and Asthma  Control
Test (ACT)  as  a  comparator.  The  associations  between  asthma  patients  without  AR  (AsAR)  and
with AR  (AwAR)  were  analyzed  with  Spearman  correlation.  Additionally,  Receiver  Operating
Characteristic  (ROC)  curve  analysis,  summarized  by  Area  Under  the  Curve  (AUC),  was  used  to
assess performance  of  CARAT  for  screening  asthma  that  was  not  well-controlled.
Results:  A total  of  103  asthma  patients  completed  the  study,  64  (62%)  had AwAR  and
in 87  (85%)  asthma  was  not  well-controlled.  We  observed  a  strong  correlation  between
CARAT and  ACT  scores  (r = 0.734)  in  all  asthma  patients  and  in both  groups:  AsAR  (r  =  0.737)
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and  AwAR  (r  = 0.843).  ROC  curve  demonstrated  CARAT  as  having  a  good  discriminative  power
for both  AsAR  and AwAR  groups  (AUC  = 0.894  and  0.946,  respectively).
Conclusion:  These  initial  results  suggest  that  CARAT  has  a  good  discriminative  performance,
similar to  other  asthma  control  assessment  tools,  for  asthma  patients  with  and without  AR.
© 2015  Sociedade  Portuguesa  de Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
The  ‘‘Allergic  Rhinitis  and  its  Impact  on  Asthma’’  (ARIA)
highlights  a  close  relationship  between  asthma  and  Aller-
gic  Rhinitis  (AR)  and recommends  a combined  approach  to
evaluate  and  manage  these two  conditions.1
The  Control  of Allergic  Rhinitis  and  Asthma  Test  (CARAT)
was  the  first  questionnaire  to  assess  the  level of  control
of  both  asthma  and  AR  using  a single  tool.2,3 CARAT  was
developed  using  a  thorough  formal methodological  approach
and  the  validation  studies  showed  it  has  the good  measure-
ment  properties  observed  fulfilling  the  ten items  on  the
COnsensus-based  Standards  for  the  selection  of health  Mea-
surement  Instruments  (COSMIN).3 It is  a Patient-Reported
Outcome  that  quantifies  the  degree  to  which  therapy  goals
are  met  in  patients  with  a previous  diagnosis  of  AR and
asthma  and can  be  used at all  levels  of  care.4--6As  CARAT’s
properties  have  been  tested  in patients  with  both  asthma
and  rhinitis,  the  aim  of this  study  was  to  test  the hypothesis
that  CARAT  can  be  used  to  assess  asthma  control  in  patients
with  asthma  and  without  AR.
Methods
A  cross-sectional  study  was  conducted  in Caldas  das  Taipas,
a  sub-urban  area  of  Northern  Portugal.  All adult  patients
cared  for in one  of  the  three  primary  care  centres  (PCC),
between  November  and  December  2010,  with  an asthma
diagnosis  registered  on  the Electronic  Patient  Record  (EPR),
were  eligible  for  the study.  The  exclusion  criteria  were:  mis-
diagnosis/coding  error  confirmed  by  both  the patient  and
the  family  doctor;  physical  or  cognitive  disabilities  that  pre-
vented  the  completion  of  the  questionnaire;  patients  that
could  not  attend  an appointment.  A letter  was  sent  to  all  eli-
gible  patients,  explaining  the aim  of  the project  and  inviting
them  to  participate.
The  Ethics  Committee  of  the Regional  Health  Adminis-
tration  approved  the  study. Written  informed  consent  was
obtained  from  each  participant.
Participants  were classified  has having  AR  based  on  the
presence  of  two  or  more  of  five  symptoms,  as  recommended
by  ARIA  guidelines.1
CARAT  has  10  questions  and a  rating  scale  from 0 to  30,
with  a  cut-off  value of  24  points  to  classify  patients:  not
well-controlled  (≤24)  and  controlled  asthma  (>24).4 The
Asthma  Control  Test  (ACT)7 was  used  as  a comparator  for
asthma  control  using a cut-off  of  >19,  well  controlled,  and
≤19,  not  well-controlled.  For assessing  AR  symptoms,  the
Visual  Analog  Scale  (VAS)  was  used,  ranging  from  0  cm  (good)
to  10  cm  (bad),  with  a  cut-off  of  5.5  cm  for  mild  versus  mod-
erate/severe  rhinitis.
Statistical  analysis  was  performed  using  IBM  SPSS  v21
(Armonk,  NY;IBM  Corp.).  The  associations  between  CARAT
with  ACT  scores  in asthma  patients  without  AR  (AsAR)  and
with  AR  (AwAR)  were  analyzed  by  Spearman  correlation.
Receiver  Operating  Characteristic  (ROC) curve analysis  was
used  to  assess  the  performance  of  CARAT  score  against  ACT,
summarized  using  the Area Under  the  Curve  (AUC).  A  signif-
icance  level  of   ˛ < 0.05  was  considered.  A power  analysis  for
2  independent  proportions  was  conducted  post  hoc.
Results
Of  the 192  patients  identified  103  participated  --  29 could
not  be contacted,  5 refused  to  participate,  20  missed  >1
appointments,  7  were  misdiagnosed  and 28  (15%)  were
unable  to  complete  the  questionnaire.  The  participation
rate  of  eligible  patients  was  72%.
From  the  103  patients  included,  64  (62%)  had  AwAR
(Table 1).  Eighty-seven  participants  (85%) were classified  as
having  not well-controlled  asthma  based  on  the  CARAT  score
and  56  (54%) by  the  ACT  score.  In  the  group  of  AwAR  a higher
proportion  were  classified  as  having  not  well-controlled
asthma  both  by  CARAT  and ACT,  97%  and  61%, respectively,
which  compares  with  64%  and  44%  in  AsAR  group  (Table 1).
There  was  a strong  and significant  correlation  between
ACT  and  CARAT  scores  in all asthma  patients  (r  =  0.734)
and  in both  AsAR  and  AwAR  groups  (r  = 0.737  and  r = 0.843,
respectively)  (Fig.  1).
The  performance  of  CARAT  for  detecting  not well-
controlled  asthma,  using  ACT  as  comparator  was  plotted  as
ROC  curves  and the respective  AUC were  0.885  for  all  asthma
patients,  0.894  for AsAR  group  and 0.946  for  AwAR  (Fig.  1).
Discussion
This study  was  the first  to  test  CARAT  for  evaluating  asthma
control  in patients  without  AR.  Overall  our  results  suggest
that  CARAT  performed  well  in assessing  the level  of  asthma
control  regardless  of  whether  patients  had  rhinitis  or  not.
The  correlations  between  CARAT  and  ACT  were  higher  than
0.73  and  the AUC  higher  than  0.88.  These  were  slightly
lower  than  those  between  Asthma  Control  Questionnaire
(ACQ)  and  ACT  (r = −0.87  to  −0.89; AUCs  =  0.85--0.90)  and
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Table  1  Characterization  of  all  asthma  patients  and  in  both  groups:  AsAR  and  (AwAR).
Total
n  =  103
AsAR
n  =  39
AwAR
n  = 64
Gender,  n  (%)
Male  26  (25) 11  (28)  15  (23)
Female 77  (75) 28  (72)  49  (77)
Age, years
Mean  (SD) 49.51  (18.07) 56.87  (17.4) 45.03  (17.07)
Min--Max 18--88 22--88 18--88
Ever smoked,  n  (%)
Yes  19  (18) 8  (20)  11  (17)
No 84  (82) 31  (80)  53  (83)
CARAT score
Median  (IQR)  17  (11--22)  23  (18--26)  13  (10--18)
Asthma overall  control  by  CARAT,  n  (%)
Not well-controlled  87  (85) 25  (64)  62  (97)
Controlled 16  (15) 14  (36)  2 (3)
VAS --  rhinitis,  median  (IQR)  4.8  (0--7.8)  0  (0--0)  5.95  (4.8--8.4)
Mild rhinitis,  n  (%)  65  (64) 35  (92)  30  (47)
Moderate/severe  rhinitis,  n  (%)  37  (36) 3  (8)  34  (53)
ACT score
Median  (IQR)  19  (14--22)  20  (17--22)  18  (13--22)
Asthma control  by  ACT,  n  (%)
Not well-controlled  56  (54) 17  (44)  39  (61)
Controlled 47  (46) 22  (56)  25  (39)
AsAR: asthma without allergic rhinitis; AwAR: asthma with allergic rhinitis; CARAT: Control of Allergic Rhinitis and Asthma Test; ACT:
Asthma Control Test; VAS: Visual Analog Scale; SD: standard deviation; Min--Max: Minimum--Maximum; IQR: interquartile range.
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Figure  1  Receiver  Operating  Characteristic  (ROC)  curves  and  the  respective  correlation  of  CARAT  score  against  ACT,  for  screening
not well-controlled  asthma,  in all patients  and  both groups:  AsAR  and  AwAR.  AsAR:  asthma  without  allergic  rhinitis;  AwAR:  asthma
with allergic  rhinitis.  AUC:  Area  Under  the  Curve;  r  de  Spearman;  *  p  <  0.05.
similar  to those  between  ACQ  and Asthma  Control  Scoring
System  (ACSS).8--10 The  difference  observed  in the  proportion
of control  measured  with  CARAT  and  ACT  was  also  reported
in  a  study  conducted  in Portuguese  pharmacies,  suggesting
that  CARAT  may  have  more  sensitivity  as  an  asthma  control
screening  test  in the  community.6 A possible  explanation
for  the  differences  in the  classification  of  asthma  control
between  CARAT  and  ACT  may  be  the inclusion  in ACT  of  the
question  ‘‘How  would  you rate  your  asthma  control  during
the  past  4  weeks?’’  In patients  who  do not perceive  poor
control,  this  question  may  decrease  the sensitivity  to  detec-
ting  poor  control.  In  fact,  in  the  Portuguese  Asthma  survey
we  observed  that  88%  of  not  well-controlled  asthma  patients
stated  their  disease  was  controlled  when  answering  a ques-
tion  similar  to  the ACT  question.11
The  main  limitation  of  this  study  is  not  having  the  physi-
cian’s  assessment  of asthma  control  to  compare  with  the
CARAT  score,  however,  this  sample  can  potentially  lead  to
generalizable  results  which  can  answer  our  study  aim,  as
these  patients  were  followed  in  primary  care, by  family
doctors.  ACT  is  a  well-known  asthma  control  assessment
tool,  used frequently  in  Portugal,  even  though  no clinical
validation  study  of  the  Portuguese  (European)  version  has
been published.  The  study  has  an  adequate  statistical  power
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(1  − ˇ  =  0.662)  and  the participation  rate  was  good  for  this
type  of  study.  However,  the  sample  size  is  a  limitation  as
it  does  not  allow  for  further  subgroup  analysis.  The  inclu-
sion  of  patients  with  a  registered  diagnosis  of  asthma  in the
EPR  is  both  a strength  and  limitation  of  the  study,  because
it  reduces  the probability  of  including  patients  with  dis-
eases  other  than  asthma  (specificity)  and  at the same  time,
many  patients  with  asthma,  perhaps  less  severe  asthma,
were  probably  not  registered  in the EPR. Finally,  the  high
level  of  not  well-controlled  asthma  observed  may  be par-
tially  explained  by  the  study  design.  There  is  a  need  for
studies  conducted  in different  healthcare  settings,  in pri-
mary,  secondary,  tertiary  care  to  assess  the prevalence  of
uncontrolled  asthma  in different  situations.
In  conclusion,  the  results  obtained  from  this  study  sup-
port  the  use  of  CARAT  to  evaluate  the control  of  asthma  not
only  in  patients  with  rhinitis  but  also  in patients  without  AR.
Further  studies  are  needed  to  confirm  the applicability  of
CARAT  in  asthma  patients  without  rhinitis.
Ethical  disclosures
Protection  of  human  and  animal  subjects.  The  authors
declare  that  no  experiments  were  performed  on  humans  or
animals  for  this study.
Confidentiality  of  data. The  authors  declare  that  they have
followed  the  protocols  of  their  work  center  on  the publica-
tion  of  patient  data.
Right  to  privacy  and  informed  consent.  The  authors
declare  that  no  patient  data  appear  in this article.
Funding
The  study  required  no  additional  external  funding.  The
statistical  analysis  was  conducted  with  the  support  of
the  CARAT  Project  CINTESIS  belonging  to  the Faculty  of
Medicine,  University  of  Porto.
Conflicts of  interest
João  A.  Fonseca,  MD, PhD  is  the  coordinator  of  the CARAT
project.  The  authors  declare  that  they  have  no  conflicts  of
interest  in  relation  to  this  study.
Acknowledgements
The  authors  would like  to  acknowledge  to  Cláudia  Camila
Dias  for  help  in the statistical  analyses.
References
1. Bousquet J, Khaltaev N, Cruz A. Allergic Rhinitis and its Impact
on Asthma (ARIA). Allergy. 2008;63 April (Suppl. 86):8--160,
http://dx.doi.org/10.1111/j.1398-9995.2007.01620.x.
2. Nogueira-Silva L,  Martins SV, Cruz-Correia R, Azevedo LF,
Morais-Almeida M, Bugalho-Almeida A,  et al. Control of aller-
gic rhinitis and asthma test -- a formal approach to the
development of  a measuring tool. Respir Res. 2009;17(10):52,
http://dx.doi.org/10.1186/1465-9921-10-52.
3. Fonseca JA, Nogueira-Silva L,  Morais-Almeida M, Azevedo L, Sa-
Sousa A, Branco-Ferreira M,  et  al. Validation of a  questionnaire
(CARAT10) to assess rhinitis and asthma in patients with asthma.
Allergy. 2010;65:1042--8.
4. Azevedo P, Correia de Sousa J, Bousquet J, Bugalho-Almeida A,
Del Giacco SR, Demoly P, et al.  Control of  Allergic Rhinitis and
Asthma Test (CARAT): dissemination and applications in primary
care. Prim Care Respir J.  2013;22(1):112--6.
5. van der Leeuw S,  van der Molen T,  Dekhuijzen PNR, Fonseca
JA, van Gemert FA, Gerth van Wijk R, et  al. The minimal clini-
cally important difference of the control of  allergic rhinitis and
asthma test (CARAT): cross-cultural validation and relation with
pollen counts. NPJ Prim Care Respir Med. 2015:25.
6. Lourenc¸o  O, Calado S,  Sá-Sousa A, Fonseca JA. Evalua-
tion of  allergic rhinitis and asthma control in a Portuguese
community pharmacy setting. J Manage Care Pharm: JMCP.
2014;20(5):513--22.
7. Roxo JP, Ponte EV, Ramos DC, Pimentel L,  D’Oliveira A, Cruz A.
Portuguese-language version of the Asthma Control Test. J  Bras
Pneumol. 2010;36(2):159--66.
8. Schatz M,  Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA,
et  al. Asthma Control Test: reliability, validity, and responsive-
ness in patients not  previously followed by asthma specialists.
J Allergy Clin Immunol. 2006;117(3):549--56.
9. Zhou X, Ding FM, Lin JT, Yin KS. Validity of asthma control test
for  asthma control assessment in Chinese primary care settings.
Chest. 2009;135(4):904--10.
10. Leblanc A, Robichaud P, Lacasse Y, Boulet LP. Quantification of
asthma control: validation of the  Asthma Control Scoring Sys-
tem. Allergy. 2007;62:120--5.
11. Sá-Sousa A, Amaral R,  Morais-Almeida M, Araújo L, Azevedo
LF, Bugalho-Almeida A, et  al. Asthma control in the Por-
tuguese National Asthma Survey. Rev Port Pneumol. 2015;21(4):
209--13.
Documento descargado de http://www.elsevier.pt el 01/10/2016. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
